Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
 

Ministerstvo zahraničních xxxx sděluje, xx xxx 1. xxxxx 2023 xxxx generální xxxxxxxxxx UNESCO xxxxxxxx xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxx zakázaných xxxxx x xxxxx xxxxxxx xxx xxx 2024 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx ve sportu.

S xxxxx zněním Xxxxxxx X vyslovil xxxxxxx Xxxxxxxxx České xxxxxxxxx x prezident republiky xxxxxxxx listinu o xxxxxxx změn Xxxxxxx X Xxxxxx republikou.

Nové xxxxx Xxxxxxx X xxxxxxxxx v xxxxxxxx x xxxxxxx x článkem 34 odst. 3 Xxxxxx xxx 1. xxxxx 2024, pro Xxxxxx republiku xxxxxxxxx x platnost xxx 18. xxxxxx 2024 x nahradilo Přílohu X xxx xxx 2023, platnou od 1. xxxxx 2023, xxxxx xxxxxxxxx v xxxxxxxx xxx Xxxxxx xxxxxxxxx dne 22. xxxxxx 2023 x xxxx vyhlášena pod č. 32/2023 Sb. m. s.

Xxxxxxxx xxxxx Přílohy X xxx rok 2024 x xxxx xxxxxxx do xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;

Xxxxxxx:

x z. XXXx. Xxxxxx, Xx.X., XX.X., x. x.

xxxxxx xxxxxxx xxxxx právní x xxxxxxxxxx
&xxxx;

Xxxxxxx x. 1

Překlad xxxxxxxxxxx smlouvy xx xxxxxxx jazyka

Úvod

Seznam xxxxxxxxxx xxxxx a xxxxx xxxxxxx je xxxxxxx Xxxxxxxxxxx standard v xxxxx Xxxxxxxxx antidopingového xxxxxxxx.

Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx antidopingovou xxxxxxxxx (XXXX). Seznam xx xxxxxx xx 1. xxxxx 2024.

Oficiální xxxx Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxx xxxxxxxxx WADA x xxxx publikován v xxxxxxxxxx a xxxxxxxxxxxxx. X xxxxxxx jakýchkoliv xxxxxxxxxxxxx xxxx xxxxxxxxx x francouzským xxxxxx xxxxxxxxx xxxxx x xxxxxxxxxx.

Xxxx jsou xxxxxxx xxxxxxx xxxxx používané x xxxxx Xxxxxxx xxxxxxxxxx xxxxx x xxxxx.

Xxxxxxxx Xxx xxxxxxx

Xxxxx XXXX xxx xxxx xxxxx neschválila xxxx xxxxxx, xx období Xxx soutěži x xxxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxx xxxxxxx (xx 23:59 hodin) x xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx xx xx Xxxxxxxxx xxxxxxxxx, xx do xxxxx Xxxxxxx x xxxxxxx xxxxxx Vzorku.

Zakázané xxxxx

Xx xxxxxxx, že daná xxxxx xxxx xxxxxx xx xxxxxxxx Xxx xxxxxxx x Xxxx xxxxxx, jak xx xxxxxxxxxx x Kodexu.

Specifické x Nespecifické

Podle xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx Xxxxxx „xxx xxxxx xxxxxxxx xxxxxx 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Specifickými xxxxxxx, x výjimkou xxxx xxxxxxxxxx x Xxxxxxx xxxxxxxxxx látek x xxxxx xxxxxxx. Xxxxx Xxxxxxxx xxxxxx xxxxxx Xxxxxxxxxxx metodou, xxxxx xxxx v Xxxxxxx xxxxxxxxx xxxxxxxx xxxx Xxxxxxxxxx metoda.“ Podle xxxxxxxxx x článku „Xxxxxxxxxx xxxxx a Xxxxxxxxxx xxxxxx xxxxxxx x článku 4.2.2 xx xxxxxx xxx xxxxxx xxxxxxxx považovány xx xxxx důležité xxxx xxxx xxxxxxxxxx xxx xxxx dopingové xxxxx nebo xxxxxx. Xxx xxxxx x xxxxx x xxxxxx, xxxxx Sportovec pravděpodobně xxxx nebo xxxxxx x jinému xxxxx xxx ke xxxxxxxx xxxxxxxxxxx xxxxxx.“

Xxxxxxxx xxxxx

Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx látky xxxxxxxxxx xxxx xxxxx, xxxxx xxxx jako xxxxxx označeny x xxxxxx xxxxxx xxxxxxx xxxxxxxxxx xx xxxxxxxxxxx xxxx xxxxx sportu. Xxxx Návykové látky xxxx označovány xxxx xxxxx: xxxxxx, diamorfin (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).

X0 XXXXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx látky.

Jakákoliv xxxxxxxxxxxxxx látka, na xxxxxx se nevztahuje xxxxx x následujících xxxxxx Xxxxxxx x xxxxx xxxx x xxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx pro xxxxxxx xxxxxxx u xxxx (např. xxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx nebo xxxxxxx vývoj xxx xxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx pouze xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx xxxxx.

Xxxx xxxxx xxxxxxxx xxxxx xxxxxxx látek, xxxx xxxx BPC-157, 2,4-xxxxxxxxxxxx (XXX) a xxxxxxxxxx xxxxxxxxx (např. Xxxxxxxxxxx x Xxxxxxxxxx).

X1 XXXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx látky x xxxx třídě xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

X1.1. XXXXXXXXXX XXXXXXXXXX STEROIDY (XXX)

Xxx exogenním podání, xxxx xxxx xxxxxx:

•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)	&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;	&xxxx;•&xxxx;	xxxxxxxxxx
•	1-xxxxxxxxxxxxxx (5ɑ-androst-1-en-3,17-dion)		•	furazabol (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx)
•	1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxx
•	1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx)		&xxxx;•	xxxxxxxxxx
•	4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx)
•	4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx)		&xxxx;•	xxxxxxxxx
•	5-xxxxxxxxxxxxxx (androst-5-en-3,17-dion)		•	metandriol
•	7ɑ-hydroxy-DHEA		•	metasteron (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)
•	7-xxxx-XXXX		&xxxx;•	xxxxxxxxxxxxxx
•	11ß-xxxxx-19-xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx (17β-hydroxy-17α-metylestra-4,9-dien-3-on)
•	17ɑ-methylepithiostanol (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17ɑ-metylestr-4-en-3-on)
•	19-norandrostenediol (estr-4-en-3,17-diol)		•	metyltestosteron
•	19-norandrostenedion (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-dihydrotestosteron, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxx (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (androsta-1,4-dien-3,17-dion)		•	oxandrolon
•	calusteron		•	oxymesteron
•	klostebol		•	oxymetolon
•	danazol ([1,2]oxazolo[4’,5’:2,3]pregna-4-en- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (dehydroepiandrosteron, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx)		&xxxx;•	xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-methyl-5ɑ-androst-2-en-17ß-ol x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- ol)		•	quinbolon
•	dimetandrolon (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-hydroxy-5α-androstan-17-on)		•	testosteron
•	epi-dihydrotestosteron (17β-hydroxy-5β-androstan-3-on)		•	tetrahydrogestrinon (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx)		&xxxx;•	xxxxxxxxx (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX)

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X1.2. XXXXXXX ANABOLICKÉ LÁTKY

Mimo xxxx xxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů [SARM, xxxx. andarin, xxxxxxxxx (xxxxxxx), LGD-4033 (xxxxxxxxx), XXX140, S-23 x XX-11], xxxxxxx a xxxxxxxxxx.

X2 XXXXXXXXX XXXXXXX, XXXXXXX FAKTORY, PŘÍBUZNÉ XXXXX X XXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)

Všechny xxxxxxxx látky x xxxx třídě xxxx Xxxxxxxxxxxx látky.

Následující xxxxx x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx jsou xxxxxxxx.

X2.1. XXXXXXXXXXXXX (EPO) X XXXXX XXXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx včetně:

S2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. darbepoetiny (xXXX); xxxxxxxxxxxxx (EPO); xxxxxxxxxx xxxxxxxx xx XXX, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; EPO- xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx, např. XXXX-530, xxxxxxxxxxx.

X2.1.2 Aktivační xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), např. xxxxxx; xxxxxxxxxxx (GSK1278863); XXX2; xxxxxxxxxx (XXX 85-3934); xxxxxxxxxx (FG-4592); xxxxxxxxxx (XXX-6548); xxxxx.

X2.1.3 Xxxxxxxxxx XXXX, xxxx. X-11706.

X2.1.4 Inhibitory xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (XXX-β), xxxx. xxxxxxxxxxxx; sotatercept.

S2.1.5 Agonisté xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. asialo XXX; xxxxxxxxxxxxx EPO (CEPO).

S2.2. XXXXXXXXX XXXXXXX X XXXXXX XXXXXXXXXX XXXXXXX

X2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x xxxx, xxxx xxxx včetně:

• xxxxxxxx xxxxxxxxxxxx (CG),

• xxxxxxxxxxxx xxxxxx (XX),

• hormon xxxxxxxxxx gonadotropin (GnRH, xxxxxxxxxxx) x jeho xxxxxxxxxxx analogy (xxxx. xxxxxxxxx, xxxxxxxxxx, goserelin, xxxxxxxxx, xxxxxxxxxxx, nafarelin x xxxxxxxxxxx),

&xxxx;• kisspeptin x xxxx xxxxxxxxxxx xxxxxxx.

X2.2.2 Kortikotropiny a xxxxxx uvolňující faktory, xxxx. kortikorelin x xxxxxxxxxxxxx.

X2.2.3 Růstový hormon (XX), jeho xxxxxxx x xxxxxxxxx, xxxx xxxx včetně:

• analogy xxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,

• xxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. XXX-9604 x xXX 176–191.

S2.2.4 Xxxxxxx uvolňující xxxxxxx xxxxxx, xxxx xxxx xxxxxx:

• xxxxxx xxxxxxxxxx xxxxxxx hormon (XXXX) x jeho xxxxxxx, xxxx. XXX-1293, CJC-1295, xxxxxxxxxx a xxxxxxxxxxx,

• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) a xxxxxx xxxxxxxx [xxxx. anamorelin, xxxxxxxxxxxx, ibutamoren (XX-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx x xxxxxxxxxxx],

• xxxxxxx xxxxxxxxxx XX (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (hexarelin), GHRP-1, XXXX-2 (xxxxxxxxxxx), GHRP-3, XXXX-4, GHRP-5 x XXXX-6].

X2.3. XXXXXXX XXXXXXX X MODULÁTORY XXXXXXXXX XXXXXXX

Xxxx xxxx xxxxxx:

• xxxxxxxxxxxxx růstové xxxxxxx (XXX)

• xxxxxxxxxxxx růstový xxxxxx (HGF)

• růstový xxxxxx 1 podobný xxxxxxxx (XXX-1, mecasermin) x xxxx xxxxxxx

• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF)

• xxxxxxxx-β4 x xxxx xxxxxxxx, xxxx. TB-500

• vaskulárně-endoteliární xxxxxxx xxxxxx (XXXX)

x xxxxx růstové xxxxxxx xxxx xxxxxxxxxx růstových xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx xx xxxxxxx, xxxxxxxx nebo vazech, xxxxxxxxxxxxx, xxxxxxx energie, xxxxxxxxxxxxx kapacitu nebo xxxxxxxxxxx typy xxxxxxxxx xxxxxx.

X3 XXXX-2 XXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx látky v xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxx x neselektivní xxxx-2 xxxxxxxx včetně xxxxx xxxxxxxxx xxxxxxx xxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Inhalační xxxxxxxxxx: xxxxxxxxx 1600 mikrogramů xx 24 xxxxx x xxxxxxxxxx dávkách, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 hodin xx xxxxxxxxx dávce;

• xxxxxxxxx formoterol: maximálně xxxxxx dávka 54 xxxxxxxxxx za 24 xxxxx;

• xxxxxxxxx salmeterol: xxxxxxxxx 200 mikrogramů xx 24 hodin;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 25 xxxxxxxxxx xx 24 xxxxx.

XXXXXXXX

Xxxxxxxxxx salbutamolu x xxxx x xxxxxxxx vyšším xxx 1000 ng/ml nebo xxxxxxxxxxx v množství xxxxxx xxx 40 xx/xx neodpovídá xxxxxxxxxxxxxx xxxxxxx látky a xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), pokud Sportovec xxxxxxxxx kontrolovanou xxxxxxxxxxxxxxxxx xxxxxx, že xxxxxxxxxx xxxxxxxx xxx důsledkem xxxxxxxxxxxx xxxxx (inhalační) xx xx výše xxxxxxx xxxxxxxxx dávky.

S4 XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX I XXXX XXXXXX)

Xxxxxxxx xxxxx xx xxxxxxx X4.1 x X4.2 jsou Specifické xxxxx.

Xxxxx zařazené xx xxxx S4.3 x X4.4 xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxxxxxx a xxxxxxxxxxx modulátory xxxx xxxxxxxx.

X4.1. XXXXXXXXXX AROMATÁZ

Mimo xxxx xxxxxx:

•	2-xxxxxxxxxxx (5ɑ-androst-2-en-17-ol)		•	androsta-1,4,6-trien-3,17-dion (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-3,5-xxxx-7,17-xxxx (xxxxxxxxx)
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-androst-3-en-17-on)		•	formestan
•	4-androsten-3,6,17 xxxxx (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. ANTIESTROGENNÍ XXXXX [XXXXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXX ESTROGENOVÝCH XXXXXXXXX (XXXXX)]

Xxxx jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. LÁTKY XXXXXXXXXXX XXXXXXXX XXXXXXXXX XXXXXXXX XXX

Xxxx jiné xxxxxx:

•	xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx A		•	inhibitory xxxxxxxxxx, xxxx.:
•	xxxxxxxxxx xxxxxxxxx xxxxxxxx XXX, xxxx.:			- xxxxx xxxxxxxxx xxxx xxxxxx xxxxxxx xxxxxxxxxx
	- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. XXX-031)			- xxxxxxxx xxxxxx myostatin (xxxx. xxxxxxxxxxx, propeptid xxxxxxxxxx)
•	xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx XXX (xxxx. xxxxxxxxxx)			- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx prekurzory (xxxx. xxxxxxxxxxx, xxxxxxx xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx)

X4.4. METABOLICKÉ XXXXXXXXXX

X4.4.1 xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (AMPK), např. XXXXX, agonisté xxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) xxxxxxxx xxxxxx (XX1516, XX501516) x xxxxxxxx Xxx-xxxɑ , např. XX9009, XX9011

X4.4.2 xxxxxxxx x xxxxxxxx xxxxxxxx

X4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX X XXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx jsou Specifické xxxxx.

Xxxxxxx xxxxxxxxx x xxxxxxxxx xxxxx, včetně xxxxx xxxxxxxxx xxxxxxx, xxxx. d- a x-, jsou xxxxxxxx.

Xxxx xxxx včetně:

•  Xxxxxxxxx, xxxx např.:

acetazolamid; amilorid; xxxxxxxxx; kanrenon; chlortalidon; xxxxxxxx etakrynová; xxxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx, např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x hydrochlorothiazid; xxxxxxxxx; xxxxxxxxxx;

• Xxxxxxx, xxxx. konivaptan, xxxxxxxxxx, xxxxxxxxx;

• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, např.:

albumin, xxxxxxx, xxxxxxxxxxx xxxxx, xxxxxxxx;

• Desmopresin;

• Xxxxxxxxxx;

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx.

XXXXXXX

• xxxxxxxxxxx; xxxxxxxx; x xxxxxxx oftalmologické xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxxx);

• xxxxxxx podání xxxxxxxxxxx x xxxxx anestezii.

POZNÁMKA

Nález xxxxxxxxxxx množství látky xx stanoveným xxxxxxxx xxxxxxx: x formoterolu, xxxxxxxxxxx, xxxxxx, efedrinu, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Vzorku Xxxxxxxxx xxxxxxxx xxxx xxxxxxxx Xxx Soutěži ve xxxxxxx x diuretikem xxxx xxxxx xxxxxxxxx xxxxxx (xxxxx lokálního xxxxxx podání inhibitoru xxxxxxxxxxxxxx nebo xxxxxxxxx xxxxxx felypresinu x xxxxxxxx anestezii), bude xxxxxxxxx xx Pozitivní xxxxxxxxxxx nález (AAF), xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) na xxxx xxxxx xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx metody v xxxx xxxxx xxxx Xxxxxxxxxxxx x xxxxxxxx xxxxx x X2.2, xxx xxxx Xxxxxxxxxx xxxxxx.

X1. XXXXXXXXXX S XXXX X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X1.1. Xxxxxx nebo opětovné xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxx x xxxxxxxxx krvinek xxxxxxxxxxx xxxxxx do xxxxxxxxx xxxxxxx x xxxxxxxx xxxxxxxx plazmy xxxx xxxxxx složek Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxxxx xxxxxxxxx xxxxxx.

X1.2. Xxxxx xxxxxxxxx xxxxxx, xxxxxxx xxxx xxxxxxx kyslíku.

Mimo jiné xxxxxx:

Xxxxxxxxxxxxxxxxxxx; efaproxiral (XXX13); xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, xxxx. xxxxxx náhražky xx xxxx xxxxxxxxxxx x xxxxxxxxxxxxxxxx hemoglobinové xxxxxxxx, x výjimkou xxxxxxxxxxx xxxxxxx xxxxxxxx.

X1.3. Jakákoliv xxxxx intravaskulární manipulace x xxxx xxxx x krevními xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

X2.1. Podvádění xxxx Xxxxx x xxxxxx xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxx a/nebo xxxxxx Xxxxxx, xxxx. xxxxxxxx xxxxxxx ke Vzorku.

M2.2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx xxxxxx 100 xx xx 12 xxxxx xxxxx infuzí legitimně xxxxxxxxx x průběhu xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxxx vyšetření.

M3. XXXXXX X XXXXXXX XXXXXX

X xxxxxx xxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx je xxxxxxxx xxxxxxxxxxx:

X3.1. Použití xxxxxxxxxx xxxxxxx nebo xxxxxx xxxxxxx, které xxxxx změnit sekvence xxxxxx x/xxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxx. Xx xxxx jiné xxxxxxxx technologie úprav xxxx, umlčování xxxx x technologie xxxxxxx xxxx.

X3.2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X6 XXXXXXXXXXX

XXXXXXXX PŘI XXXXXXX

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx látky x xxxxxxxx xxxxx xxxxxxxxx x S6.A, xxx xxxx Nespecifické xxxxx.

Xxxxxxxx xxxxx v xxxx xxxxx: kokain x metylendioxymetamfetamin (XXXX/„xxxxxx“)

Xxxxxxx xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx izomerů, např. x- x x-, xxxx zakázána.

Stimulancia xxxxxxxx:

X6.X: XXXXXXXXXXXX XXXXXXXXXXX

•	xxxxxxxxx		•	xxxxxxxxxxxx [4-xxxxxxxxxxxxxx (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, xxxxx není xxxxxxxx xxxxxx x xxxxx xxxxxx, xx Xxxxxxxxxxx xxxxxx.

X6.X: XXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)		•	xxxxxxxxxxx		•	xxxxxxxxx
•	3-xxxxxxxxxx-2-xxxx (1,2-dimetylpentylamin)		•	fenbutrazát		•	oxilofrin (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx)		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	4-xxxxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxx (xxxxxxxxx)		•	xxxxxxxxxxx x xxxx xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-dimetylamylamin, 1,4-dimetylpentylamin, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (parahydroxyamfetamin)		•	fenmetrazin
•	benzfetamin		•	isomethepten		•	fenprometamin
•	katin1)		•	levmetamfetamin		•	propylhexedrin
•	katinon a xxxx analogy, xxxx. xxxxxxxx, xxxxxxxx x ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)		•	xxxxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxx3)		•	xxxxxxxxxxxx3)		•	xxxxxxxxxx
•	xxxxxxxxx (adrenalin)4)		•	metylnaftidát [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx]		•	xxxxxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx)
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x další látky x podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky

VÝJIMKY

• xxxxxxxx;

• xxxxxxxx xxxxxxxxxxx x xxxxxxx jejich xxxxxxx, xxxxxxx, očního nebo xxxxxx xxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, nafazolin, oxymetazolin, xxxxxxxxxx, xxxxxxxxxx, xylometazolin) x xxxxxxxxxxx zařazená xx Monitorovacího xxxxxxxx 2024⁵⁾.

X7 XXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx látky x xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx x této xxxxx: xxxxxxxxx (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx xxxxx optických xxxxxxx, např. d- x l, jsou xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx x xxxx xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (heroin)		•	metadon		•	oxykodon		•	tramadol
						•	oxymorfon

S8 KANABINOIDY

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Specifické xxxxx. Xxxxxxxx xxxxx x této xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx přírodní x xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx, xxxx.

• x konopí (xxxxx, xxxxxxxxx) a xxxxxxxxx xxxxxxxxxx

• přírodní a xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)

• xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxx THC

VÝJIMKY

• kanabidiol

S9 XXXXXXXXXXXXXXX

XXXXXXXX PŘI XXXXXXX

Xxxxxxx xxxxxxxx látky v xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxxxxxxx xxxx xxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, xxxxxxxxx [včetně xxxxxxxxxx (xxxx. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx xxxxxx.

Xxxx jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxxxxx

XXXXXXXX

• Jiné xxxxxxx podání (xxxxxx xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) xxxxxx zakázány, xxxxx se xxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxx.

X1 XXXX-XXXXXXXXX

XXXXXXXX X XXXXXXXX XXXXXXXX

Xxxxxxx xxxxxxxx látky v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx jsou xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx a kde xx to xxxxxxxx xxxxxxxx (*) x Xxxx xxxxxx.

• xxxxxxxxxxx (XX)*

• xxxxxxxx/xxxxxxxxxxxx (FIS) – skoky na xxxxxx, xxxxxxxxxxx xxxxx / U-rampa x xxxxxxxxx X-xxxxx / xxx xxx

• automobilový xxxxx (XXX)

• podvodní xxxxxx (XXXX)* x xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx xxxxxxxx a xxxxxxx xx xxxx

• xxxxxxxx (všechny disciplíny) (XXXX)

• xxxxx (XXX)

• xxxx (IGF)

• minigolf (XXX)

• xxxxxxx (XXXX, XXX)*

* xxxxxxxx také Xxxx xxxxxx

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx x. 2

Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxx
&xxxx;

¹⁾ xxxxx (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: je xxxxxxxx xxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx.

²⁾ xxxxxxxxxxxxx: xxxxxxxx pouze xxx xxxxxxxxxxx x xxxx xxxxx xxx 150 xxxxxxxxxx v 1 xx.

³⁾ xxxxxxx x metylefedrin: xxxxxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 10 mikrogramů x 1 ml.

⁴⁾ xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxx, xxxx, nebo xxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx.

⁵⁾ xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, pipradrol x xxxxxxxx: xxxx xxxxx xxxx xxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx 2024 x xxxxxx považovány xx Xxxxxxxx xxxxx.

Xxxxxxxxx

Xxxxxx xxxxxxx č. 19/2025 Sb. xxxxx xxxxxxxxx xxxx 28.1.2024.

Xxxxx xxxxxxxxxxxx právních norem xxxxxx právních předpisů x xxxxxxxx není xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx shora uvedeného xxxxxxxx předpisu